articleTop 1% cited

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

Journal of Clinical Oncology · 1997 · Vol. 15(6) · pp. 2403–2413

Howard A. Burris✉Malcolm J. Moore(The University of Texas Health Science Center at San Antonio)John Sahl Andersen(The University of Texas Health Science Center at San Antonio)M R Green(The University of Texas Health Science Center at San Antonio)Mace L. Rothenberg(The University of Texas Health Science Center at San Antonio)Manuel Modiano(The University of Texas Health Science Center at San Antonio)M. Christine Cripps(The University of Texas Health Science Center at San Antonio)Russell K. Portenoy(The University of Texas Health Science Center at San Antonio)Anna Maria Storniolo(The University of Texas Health Science Center at San Antonio)Peter G. Tarassoff(The University of Texas Health Science Center at San Antonio)Ryan Nelson(The University of Texas Health Science Center at San Antonio)F. Andrew Dorr(The University of Texas Health Science Center at San Antonio)Connie Stephens(The University of Texas Health Science Center at San Antonio)Daniel D. Von Hoff(The University of Texas Health Science Center at San Antonio)

View via DOI Publisher page

Abstract

This study demonstrates that gemcitabine is more effective than 5-FU in alleviation of some disease-related symptoms in patients with advanced, symptomatic pancreas cancer. Gemcitabine also confers a modest survival advantage over treatment with 5-FU.

Pancreatic and Hepatic Oncology Research Cancer Treatment and Pharmacology Pharmacological Effects and Toxicity StudiesMedicineGemcitabinePancreatic cancerInternal medicinePerformance statusCancerClinical trialRandomized controlled trialProgressive diseaseSurgery

MeSH terms

GemcitabineAdultAgedAntimetabolites, AntineoplasticDeoxycytidineFemaleFluorouracilHumansInfusion PumpsMaleMiddle AgedMorphineNarcoticsPainPancreatic Neoplasms

Citations

5,865

FWCI

31.78

field-weighted impact

References

Percentile

100%

vs. same field & year

Citations per year

Cited by

Pancreatic Cancer Chemoresistance to Gemcitabine